FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

LUPIN

859.1
-7.95 (-0.92%)
Updated 03:29 10/07 IST

LUPIN Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 1,751,503.45 for LUPIN
Disclaimer
100% Bullish
0% Bearish

LUPIN Buy or Sell - Brokerage Reports

No. of reports in last year
10
No. of analysts
5
Average Consensus Forecast
829.8
Consensus Potential
-6.26%
See LUPIN Share Price Targets >>

LUPIN Ratings

Long term LUPIN rating by FrontPage users
3.3/5 (8 Ratings)
Find answers to all your questions on live LUPIN message board: Is LUPIN buy or sell? Should I buy LUPIN shares? Why are LUPIN shares falling? Should I invest in LUPIN stock?

  1. Home
  2. LUPIN Forum

LUPIN Share Price Discussion


Type
Buy
Instrument
LUPIN
Entry Price
₹861.3
Price@Trade
₹861.3
Target Price
₹930
Stop Price
₹838
Valid Till
Jul 9, 2021 3:20 AM
Margin
₹689,040 approx for 800 Qty
Status
Active
Like
Reply
D
Reputation: -578 • Yesterday 4:28 AM

Type
Buy
Instrument
LUPIN
Entry Price
₹874
Price@Trade
₹872.75
Target Price
₹878
Stop Price
₹870
Valid Till
Jul 17, 2020 3:20 AM
Margin
₹87,400 approx for 100 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Dinesh @davdineshm
Yesterday 6:28 AM

Update
Exited before entry
Price @ Update
₹865.15
N
Reputation: 3,973 • Yesterday 4:28 AM
Zara profit jumps 45.5% to Rs 104 crore in FY20, revenue up 9.2% to Rs 1,570.54 crore
Besides, the company posted 9.24 percent growth in sales to Rs 1,570.54 crore during the year as against Rs 1,437.87 crore of the previous fiscal.
Moneycontrol
Like
Reply
H
Reputation: 9,268 • Jul 9 8:36 AM

Type
Buy
Instrument
LUPIN JUL20 FUT
Entry Price
₹870
Price@Trade
₹870
Target Price
₹890
Stop Price
₹850
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹351,441 approx for 1700 Qty
Status
Active
Like
Reply
N
Reputation: 3,973 • Jul 9 8:01 AM
Buy Lupin, target price Rs 1,040: Nomura
In FY21F the company is also likely to incur one-time additional expenses of $10 million related to the recall of Metformin extended-release tablets from the US market.
The Economic Times
Like
Reply

Type
Sell
Instrument
LUPIN JUL20 FUT
Entry Price
₹871  ₹870.25
Price@Trade
₹870.6
Target Price
₹860
Stop Price
₹874
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹176,535.94 approx for 850 Qty
Status
Exited
Exit Price
₹866.55
Net P&L
+₹3,145 (+1.78%)
Like
Reply (3)
Latest replies

Update
Entry Price Modified
Price @ Update
₹870.25
Original Entry Price
₹871
New Entry Price
₹870.25
TrackerBot @trackerbot
Jul 9 6:51 AM

Update
Trade Entered
Entry Price
₹870.25

Update
Exited
Exit Price
₹866.55
Net P&L
+₹3,145 (+1.78%)

Type
Buy
Instrument
LUPIN JUL20 860 PE
Entry Price
₹26.75
Price@Trade
₹26.75
Target Price
₹28.5
Stop Price
₹25
Valid Till
Jul 9, 2020 3:20 AM
Margin
₹22,737.5 approx for 850 Qty
Status
Target Achieved
Exit Price
₹28.5
Net P&L
+₹1,487.5 (+6.54%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jul 9 6:52 AM

Update
Target Achieved
Exit Price
₹28.5
Z
Reputation: -11 • Jul 9 6:02 AM

Type
Sell
Instrument
LUPIN
Entry Price
₹867.5
Price@Trade
₹870.9
Target Price
₹860
Stop Price
₹875
Valid Till
Jul 9, 2020 3:20 AM
Margin
₹433,750 approx for 500 Qty
Status
Validity Over
Exit Price
₹870.95
Net P&L
-₹1,725 (-0.4%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 9 7:28 AM

Update
Trade Entered
Entry Price
₹867.5
TrackerBot @trackerbot
Yesterday 4:35 AM

Update
Validity Over
Exit Price
₹870.95
Net P&L
-₹1,725 (-0.4%)

Type
Buy
Instrument
LUPIN JUL20 FUT
Entry Price
₹878
Price@Trade
₹879.1
Target Price
₹899
Stop Price
₹859
Valid Till
Jul 10, 2020 3:20 AM
Margin
₹176,437.48 approx for 850 Qty
Status
Exited
Exit Price
₹870.8
Net P&L
-₹6,120 (-3.47%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 9 3:29 AM

Update
Trade Entered
Entry Price
₹878

Update
Exited
Exit Price
₹870.8
Net P&L
-₹6,120 (-3.47%)
T
Reputation: -5,712 • Jul 9 1:22 AM

Mac on Lupin
Metformin recall casts a shadow on earnings
Immediate relaunch could protect material downside
Co’s execution has faltered over last few yrs with slew of compliance issues denting US outlook
While domestic story is robust, co needs to deliver on margins & compliance
...
Read more...
Like
Reply
L
Reputation: 2,192 • Jul 8 8:46 AM
lowkey in LUPIN
New trade: Buy LUPIN, CMP@864.65, Enter@865 Tar...

Lupin is a good buy at this price and accumulate as it fall. It may rocket in coming days and give 30-40% return in 4-5 months .
Like
Reply
L
Reputation: 2,192 • Jul 8 8:45 AM

Type
Buy
Instrument
LUPIN
Entry Price
₹865
Price@Trade
₹864.65
Target Price
₹900
Stop Price
₹830
Valid Till
Jul 15, 2020 3:20 AM
Margin
₹259,500 approx for 300 Qty
Status
Exited
Exit Price
₹878.25
Net P&L
+₹3,975 (+1.53%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 8 8:46 AM

Update
Trade Entered
Entry Price
₹865
lowkey @lowkey
Jul 9 3:08 AM

Update
Exited
Exit Price
₹878.25
Net P&L
+₹3,975 (+1.53%)

Type
Buy
Instrument
LUPIN JUL20 870 PE
Entry Price
₹34.5
Price@Trade
₹34.5
Target Price
₹37
Stop Price
₹32
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹29,325 approx for 850 Qty
Status
Exited
Exit Price
₹35.5
Net P&L
+₹850 (+2.9%)
Like
Reply (1)
Latest replies
INTRADAY Options @teamIOFno
Jul 8 7:50 AM

Update
Exited
Exit Price
₹35.5
Net P&L
+₹850 (+2.9%)
N
Reputation: 3,973 • Jul 8 5:43 AM
Lupin recalls diabetes treatment drug in the US
In a regulatory filing, the company said that it is voluntarily recalling its Metformin Hydrochloride extended-release tablets USP, 500 mg and 1000 mg products in the US.
Moneycontrol
Like
Reply
A
Reputation: -126 • Jul 8 5:41 AM

Type
Buy
Instrument
LUPIN
Entry Price
₹874.6  ₹874.4
Price@Trade
₹874.7
Target Price
₹980
Stop Price
₹840
Valid Till
Aug 7, 2020 3:20 AM
Margin
₹437,200 approx for 500 Qty
Status
Exited
Exit Price
₹875
Net P&L
+₹300 (+0.07%)
Like
Reply (3)
Latest replies
Abhinav @abhinavp
Jul 8 5:42 AM

Update
Entry Price Modified
Price @ Update
₹874.4
Original Entry Price
₹874.6
New Entry Price
₹874.4
TrackerBot @trackerbot
Jul 8 5:42 AM

Update
Trade Entered
Entry Price
₹874.4
Abhinav @abhinavp
Jul 8 6:02 AM

Update
Exited
Exit Price
₹875
Net P&L
+₹300 (+0.07%)
N
Reputation: 3,973 • Jul 8 5:41 AM
Share market update: Pharma shares advance; Aurobindo Pharma gains 3%
The Nifty Pharma index was trading 1.18 per cent up at 9994.35.
The Economic Times
Like
Reply
N
Reputation: 3,973 • Jul 8 5:21 AM
Lupin recalls diabetes treatment drug in US
Drug major Lupin Ltd on Wednesday said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release tablets in the US market.
The Economic Times
Like
Reply
M
Reputation: -2,431 • Jul 8 4:25 AM

Type
Buy
Instrument
LUPIN JUL20 FUT
Entry Price
₹877.55
Price@Trade
₹877.55
Target Price
₹1,400
Stop Price
₹500
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹711,022.45 approx for 3400 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
LUPIN
Entry Price
₹881
Price@Trade
₹879.15
Target Price
₹895
Stop Price
₹872
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹44,050 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹872
Net P&L
-₹450 (-1.02%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 8 4:02 AM

Update
Trade Entered
Entry Price
₹881
TrackerBot @trackerbot
Jul 8 5:56 AM

Update
Stoploss Hit
Exit Price
₹872
R
Reputation: 31,129 • Jul 8 2:48 AM

Type
Buy
Instrument
LUPIN JUL20 FUT
Entry Price
₹870
Price@Trade
₹872.5
Target Price
₹880
Stop Price
₹865
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹177,568.69 approx for 850 Qty
Status
Target Achieved
Exit Price
₹880
Net P&L
+₹8,500 (+4.79%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 8 3:04 AM

Update
Trade Entered
Entry Price
₹870
TrackerBot @trackerbot
Jul 8 3:40 AM

Update
Target Achieved
Exit Price
₹880
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • LUPIN - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization33,444.28
    Enterprise Value33,384.84
    Price to Earnings24.77
    Price to Book Value1.95
    Return on Capital Employed0.12
    Return on Equity0.09
    Face Value2
    Dividend Yield0.01
  • LUPIN - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    30-May-20Prabhudas LilladherBuy1,001
    10-May-20Prabhudas LilladherBuy978
    7-Feb-20Prabhudas LilladherReduce654
    26-Nov-19Nirmal BangAccumulate824
    13-Nov-19Prabhudas LilladherHold760
    LUPIN Brokerage Price Target
  • LUPIN Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 10870874.9858861.1
    Jul 8874889.65862865.4
    Jul 7875.55884.4867.2870.5
    Jul 6896899.45873875.55
    Jul 3898.8904.2890900.05
  • LUPIN Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹910.42
    30 Day Moving Average₹904.76
    50 Day Moving Average₹885.05
    100 Day Moving Average₹788.66
    200 Day Moving Average₹768.19
  • LUPIN - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue10,08012,753.15-0.21
    Operating Profit2,0864,486.12-0.54
    Profit Before Tax1,7934,179.06-0.57
    Net Income1,3443,141.33-0.57
  • LUPIN - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds17,11715,7840.08
    Total Liabilities2,5733,042-0.15
    Total Assets19,69018,8270.05
  • LUPIN - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2154,353.33-0.95
    Cash from Investing Activity-1,159-1,941.79-0.4
    Cash from Financing Activity-986-160.025.16
    Net Cash Flow-1,9312,251.52-1.86
  • LUPIN - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.070.17
    Return on Equity0.090.21
    Return on Capital Employed0.120.27
  • LUPIN - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.03
    3 Year CAGR Growth in Operating Profit-0.38
    3 Year CAGR Growth in EBIDTA-0.38
    3 Year CAGR Growth in Net Income-0.44
    3 Yr CAGR Growth - Diluted EPS-0.44
  • LUPIN - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.42
    5 Year CAGR Growth in Operating Profit0.11
    5 Year CAGR Growth in EBIDTA0.16
    5 Year CAGR Growth in Net Income0.07
    3 Yr CAGR Growth - Diluted EPS0.06
  • LUPIN - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 4:28 AM
    Zara profit jumps 45.5% to Rs 104 crore in FY20, revenue up 9.2% to Rs 1,570.54 crore
    Moneycontrol
    NewsBot
    Jul 9 8:01 AM
    Buy Lupin, target price Rs 1,040: Nomura
    The Economic Times
    NewsBot
    Jul 8 5:43 AM
    Lupin recalls diabetes treatment drug in the US
    Moneycontrol
    NewsBot
    Jul 8 5:21 AM
    Lupin recalls diabetes treatment drug in US
    The Economic Times
    NewsBot
    Jun 29 5:41 AM
    Share market update: Pharma shares mixed; Cipla up over 1%
    The Economic Times
    NewsBot
    Jun 26 10:51 AM
    Replacing China as API supplier for pharma will be a medium to long term story: Lupin
    The Economic Times
    NewsBot
    Jun 24 5:36 AM
    link
    Share market update: Pharma shares dip; Cipla down over 2%
    The Economic Times
    NewsBot
    Jun 11 11:28 AM
    Lupin gets USFDA nod to market generic anthelmintic tablets
    Moneycontrol
    NewsBot
    Jun 11 10:36 AM
    Why are pharma stocks rallying? Surajit Pal explains
    The Economic Times
    NewsBot
    Jun 10 5:26 AM
    Share market update: Pharma shares rise; Biocon gains over 2%
    The Economic Times
  • LUPIN - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020